BML Capital Management »

An2 Therapeutics shares owned by BML Capital Management

Quarter-by-quarter ownership of An2 Therapeutics (ANTX) shares owned by BML Capital Management from 13F filings

Historical chart of BML Capital Management investment in An2 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including An2 Therapeutics held by BML Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in An2 Therapeutics by BML Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $6.2M 5.7M 1.07

More positions owned by BML Capital Management

Ishares Tr 0-3 Mnth Treasry (SGOV)
Instil Bio Com New (TIL)
Atea Pharmaceuticals (AVIR)
Aclaris Therapeutics (ACRS)
Spdr Ser Tr Bloomberg 1-3 Mo (BIL)
Adverum Biotechnologies Com New (ADVM)
Tectonic Therapeutic (TECX)
An2 Therapeutics (ANTX)
Reneo Pharmaceuticals (RPHM)
Oramed Pharmaceuticals Com New (ORMP)
Achilles Therapeutics Sponsored Ads (ACHL)
Aadi Bioscience (AADI)
Connect Biopharma Hldgs Ads (CNTB)
Pmv Pharmaceuticals (PMVP)
Astrotech Corp (ASTC)

View all positions for BML Capital Management

Top funds holding An2 Therapeutics

BML Capital Management
RA Capital Management
TCG Crossover Management
Henderson Group
Vanguard Group
Acuitas Investments
Renaissance Technologies
BlackRock
BlackRock
Goldman Sachs Group
Geode Capital Management
Ghost Tree Capital
Two Sigma Advisers
Two Sigma Investments
Bridgeway Capital Management

View all funds holding An2 Therapeutics